ONO-2020 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation Associated With Alzheimer's Disease Dementia
Conditions
Agitation Associated With Alzheimer's Disease Dementia
Trial Timeline
May 1, 2025 → Mar 31, 2027
NCT ID
NCT06803823About ONO-2020 + Placebo
ONO-2020 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Agitation Associated With Alzheimer's Disease Dementia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06803823. Target conditions include Agitation Associated With Alzheimer's Disease Dementia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06803823 | Phase 2 | Recruiting |
| NCT06881836 | Phase 2 | Active |
| NCT05507515 | Phase 1 | Completed |
Competing Products
20 competing products in Agitation Associated With Alzheimer's Disease Dementia